Human Prostate Cancer Cell Line (CWR-R1)

CWR-R1 is a cell line derived from the castration-recurrent human prostate cancer CWR22 xenograft.

Highlights:

  • CWR-R1 cells have a functional androgen receptor with a single mutation (AR-H874Y) that has a broadened ligand specificity and is activated at low concentrations of testosterone or dihydrotestosterone (DHT)
  • Cells express AR full length (AR-FL), AR-V7 and PSA mRNA and protein
  • Cells can be propagated for over 50 passages and growth is increased by low levels of DHT
  • Cell line is a co-culture of epithelial and stromal fibroblasts that grow as a monolayer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. The androgen receptor (AR) helps prostate cancer cells to survive and is a target for many anti cancer research studies by looking at inhibition.

From the laboratory of Elizabeth M. Wilson, PhD, University of North Carolina at Chapel Hill.

Catalog Number Product Size AVAILABILITY Price Qty
ENC005
Human Prostate Cancer Cell Line (CWR-R1)
1 Vial 2-3 weeks
Price: $499.00
Specifications
Product Type: Cell Line
Cell Type: Prostate Cancer
Organism: Human
Accession ID: CVCL_4833
Morphology: Epithelial cells and fibroblasts
Biosafety Level: BSL-2
Subculturing: Seed CWR-R1 cells at 15 x 106/T150 flask twice/weekor split 1:3 twice a week.
Growth Conditions: 500 ml DMEM-H plus , Linoleic acid 5 µl (90 mg/ml in EtOH), Nicotinamide 0.6 g, FBS 10 ml, Pen/Strep 5 ml, ITS (insulin, transferrin, selenium) 0.5 ml,EGF (add fresh from frozen stock) 0.5 ml (10 ng/ml final). Monolayer growth increases in response to low levelsdihydrotesterone (DHT)
Cryopreservation: 20% FBS, 10% DMSO in PGM growth medium
Source: CWR22 human prostate xenograft
Comments: The CWR-R1 cell line is a co-culture of epithelial and stromal fibroblasts. Do not use cells past passage 50 or fibroblasts will take over the culture. Expand cells and freeze stocks in liquid N2. For 10 ng/ml EGF, add 10 µl to 100 ml PGM media of 100 µg/ml EGF stock. Add 1 ml sterile dH20 to 100 µg vial, store in 50 µl aliquots at -20°C. EGF is stable ~1 week in media at 4°C. Phenol red-free, serum-free medium is the same except use 500 ml Improved MEM Zinc Option (Gibco 10373-017) without adding EGF or serum.
Storage: Liquid nitrogen
Shipped: Dry Ice
Provider
From the laboratory of Elizabeth M. Wilson, PhD, University of North Carolina at Chapel Hill.
References
  1. Tan JA, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS 1997 Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450-459.
  2. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM 2001 Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898.
  3. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003 Nov 1;57(3):205-25.
  4. Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS 2005 Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11:1704-1712.
  5. Shourideh M, DePriest A, Mohler JL, Wilson EM, Koochekpour S 2016 Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line. Prostate 76:1067-1077.

If you publish research with this product, please let us know so we can cite your paper.

 
Loading...
Loading...